Streetbeat News

Equity Actions

CTRA

Recent analyst evaluations of Coterra Energy (NYSE:CTRA) show diverse outlooks, with a total of 15 analysts providing ratings ranging from bullish to bearish. The average 12-month price target for CTRA has been raised to $32.6, indicating a 4.19% increase from the previous target. Analyst actions include both upgrades and downgrades, reflecting changes in market conditions and company performance. Coterra Energy, an independent oil and gas company, faces challenges such as a -30.0% revenue decline and below-industry-standard ROE and ROA, despite a strong net margin of 26.0% and a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

May 03, 2024 | 1:00 pm

BFRI

Biofrontera announced the achievement of two milestones related to its Series B-3 Convertible Preferred Stock Warrants, which will lead to $8M in payments to the company upon exercise of these warrants.

Portfolio Pulse from Benzinga Newsdesk

May 03, 2024 | 12:55 pm

BRK

DJT

GS

MSFT

SPY

Marjorie Taylor Greene disclosed her latest stock transactions, including purchases of Berkshire Hathaway, Goldman Sachs, Microsoft, and others, while selling shares in various iShares ETFs. Notably, she did not trade in Trump's DJT. The disclosure follows a 2-year gap and adheres to the STOCK Act requirements. The stock market continues to perform well, with SPY showing a 6.5% gain this year.

Portfolio Pulse from Shanthi Rexaline

May 03, 2024 | 12:18 pm

AXL

American Axle & Manufacturing Holdings (AXL) has reiterated its FY24 sales outlook, expecting sales between $6.05B-$6.35B, in line with the $6.2B estimate. The company also targets an Adjusted EBITDA of $685M-$750M and Adjusted free cash flow of $200M-$240M, assuming capital spending of 4.0%-4.5% of sales.

Portfolio Pulse from Benzinga Newsdesk

May 03, 2024 | 12:07 pm

RNA

Avidity Biosciences (NASDAQ:RNA) has received diverse analyst ratings over the last three months, with a significant upward trend in its 12-month price target to $37.29, indicating a 62.13% increase from the previous average of $23.00. Analysts from firms like B of A Securities, Needham, Cantor Fitzgerald, and Chardan Capital have adjusted their ratings and price targets, reflecting a bullish outlook on the company. Despite this optimism, Avidity Biosciences faces challenges in revenue growth and efficiency metrics, with a notable revenue decline of -20.8% and concerns in net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

May 03, 2024 | 12:00 pm

ENOV

Recent analyst ratings for Enovis (NYSE:ENOV) show a mix of bullish sentiments with an updated average 12-month price target of $78.67, reflecting a 7.77% increase from the previous target. The company's financial performance indicates strong revenue growth, profitability, and efficient asset and debt management, positioning it favorably in the medical technology sector.

Portfolio Pulse from Benzinga Insights

May 03, 2024 | 12:00 pm

CGC

Canopy Growth Corporation (CGC) announced a financing deal expected to bring in US$50 million in gross proceeds and the exchange of approximately C$27.5 million of existing debt for a new convertible debenture, aiming to strengthen its balance sheet. The agreement with an institutional investor involves issuing a senior unsecured convertible debenture maturing five years from the closing date, set for May 2, 2024.

Portfolio Pulse from Benzinga Newsdesk

May 03, 2024 | 11:37 am

ABEO

Abeona Therapeutics has announced the pricing of an underwritten offering consisting of 12.28 million shares and pre-funded warrants to purchase an additional 6.1 million shares. The price is set at $4.07 per share and $4.0699 per pre-funded warrant, aiming to raise gross proceeds of approximately $75 million.

Portfolio Pulse from Benzinga Newsdesk

May 03, 2024 | 11:35 am

LNG

Cheniere Energy has reaffirmed its financial guidance for the year 2024, projecting a Consolidated Adjusted EBITDA between $5.5 billion and $6 billion, and a Distributable Cash Flow ranging from $2.9 billion to $3.4 billion.

Portfolio Pulse from Benzinga Newsdesk

May 03, 2024 | 11:35 am

NSC

Ancora, a shareholder in Norfolk Southern (NSC), has announced that three independent proxy advisory firms recommend NSC shareholders to vote for a change in the company's boardroom. This move suggests a significant push for corporate governance changes within Norfolk Southern, reflecting potential shifts in strategic direction or operational focus that could impact the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

May 03, 2024 | 11:07 am